Cao WH, Zhang YQ, Li XX, Zhang ZY, Li MH. Advances in immunotherapy for hepatitis B virus associated hepatocellular carcinoma patients. World J Hepatol 2024; 16(10): 1158-1168 [PMID: 39474576 DOI: 10.4254/wjh.v16.i10.1158]
Corresponding Author of This Article
Ming-Hui Li, MD, PhD, Chief Doctor, Professor, Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Peking University Ditan Teaching Hospital, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. wuhm2000@sina.com
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Cao WH, Zhang YQ, Li XX, Zhang ZY, Li MH. Advances in immunotherapy for hepatitis B virus associated hepatocellular carcinoma patients. World J Hepatol 2024; 16(10): 1158-1168 [PMID: 39474576 DOI: 10.4254/wjh.v16.i10.1158]
World J Hepatol. Oct 27, 2024; 16(10): 1158-1168 Published online Oct 27, 2024. doi: 10.4254/wjh.v16.i10.1158
Advances in immunotherapy for hepatitis B virus associated hepatocellular carcinoma patients
Wei-Hua Cao, Ya-Qin Zhang, Xin-Xin Li, Zi-Yu Zhang, Ming-Hui Li
Wei-Hua Cao, Ya-Qin Zhang, Xin-Xin Li, Zi-Yu Zhang, Ming-Hui Li, Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
Ming-Hui Li, Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Peking University Ditan Teaching Hospital, Beijing 100015, China
Co-first authors: Wei-Hua Cao and Ya-Qin Zhang.
Author contributions: Li MH conceived the idea for the manuscript; Cao WH, Zhang YQ, and Li MH reviewed the literature and drafted the manuscript; Li XX and Zhang ZY reviewed the literature and proofread the manuscript.
Supported byThe National Key Research and Development Program, No. 2022YFC2603500 and No. 2022YFC2603505; Beijing Municipal Health Commission High-Level Public Health Technical Personnel Construction Project, No. Discipline leader-03-26; The Digestive Medical Coordinated Development Center of Beijing Hospitals Authority, No. XXZ0302; The Capital Health Research and Development of Special Public Health Project, No. 2022-1-2172; and Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support, No. XMLX 202127.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ming-Hui Li, MD, PhD, Chief Doctor, Professor, Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Peking University Ditan Teaching Hospital, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. wuhm2000@sina.com
Received: June 18, 2024 Revised: August 28, 2024 Accepted: September 19, 2024 Published online: October 27, 2024 Processing time: 124 Days and 12.3 Hours
Core Tip
Core Tip: Hepatitis B virus (HBV) infection interacts with the tumor microenvironment (TME) through a highly complex and intertwined signaling pathway, which results in a special TME in hepatocellular carcinoma (HCC). Due to changes in the TME, tumor cells can evade immune surveillance by inhibiting tumor-specific T cell function through CTLA-4 and programmed cell death 1 (PD-1)/PD ligand 1. Interferons, as a class of immune factors with strong biological activity, can improve the TME of HBV-HCC through various pathways. Currently, the systematic treatment of HCC has gradually come out of the dilemma. In addition to the continuous emergence of new multi-target anti-vascular tyrosine kinase inhibitor drugs, immune checkpoint inhibitors have opened up a new avenue for the systematic treatment of HCC. Since the disease characteristics of patients included in global clinical studies are different from those of Chinese patients, whether a group of HCC patients with HBV background and poor prognosis in China can also benefit from immunotherapy is an issue of wide concern.
